Status:
UNKNOWN
Medium Dose of Cytarabine and Mitoxantrone
Lead Sponsor:
Shenzhen People's Hospital
Conditions:
Acute Myelogenous Leukemia
Chemotherapy
Eligibility:
All Genders
14-70 years
Brief Summary
By observation of the inpatients in shenzhen people's hospital,research the curative effect of the two chemotherapy schemes on AML-High dose of cytarabine and HAM.
Detailed Description
The patients of AML in shenzhen people's hospital were randomly divided into two therapy groups.One group was treated by High dose of cytarabine ,and the other was HAM.Evaluate the two chemotherapy sc...
Eligibility Criteria
Inclusion
- people diagnosed as AML
Exclusion
- acute promyeloytic leukemia
Key Trial Info
Start Date :
September 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 31 2019
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT04024241
Start Date
September 1 2017
End Date
August 31 2019
Last Update
July 18 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shenzhen
Shenzhen, Guangdong, China, 518000